Skin cancer vaccine FDA approved by December 31, 2027: the evidence and conditions to watch

What this event actually asks

The useful question is precise: Skin cancer vaccine FDA approved by December 31, 2027? In the API observation at 09:57 UTC on 2026-10-04, the selected contract’s first listed outcome was priced at 66.5%. The parent event had recorded $154,222 in cumulative volume. This is turnover across the event, not a count of independent forecasters or proof that this outcome is correctly priced. ^[1][2]

The Yes condition is that the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET. ^[2]

Promising trial results and an approval letter are separate milestones

FDA describes drug approval as a review of evidence on benefits, risks, quality and proposed labeling. Fast Track and Breakthrough Therapy are development or review designations, not interchangeable with a marketing approval. ^[3]

A positive clinical trial can make a product more promising while leaving submission, review and manufacturing questions unresolved. For a dated approval contract, those administrative steps and the eligible indication matter alongside efficacy. No market price establishes that an investigational product is safe to use.

The contract identifies intismeran autogene, also known as V940 or mRNA-4157, and explicitly allows a qualifying approval for an indication other than melanoma. A narrower population or combination regimen can also qualify. This is therefore a product-approval question rather than a requirement for a universal cancer-prevention vaccine. ^[2]

Which evidence would change the assessment?

An FDA approval letter for the product and indication allowed by the written rules would strengthen the positive outcome.

A trial result, submitted application, designation or early-access program can occur without the qualifying marketing approval.

The next useful checkpoint

Written-rule date: December 31, 2027; 11:59 PM (ET). The selected contract and any reporting grace period govern settlement. ^[2]

Our reading is conditional: compare the next primary record with the exact threshold above, then revisit the case if the evidence contradicts it. A high quoted chance does not establish certainty; a low quote does not make the event impossible. The value of the article is a clearer test of the claim, not an asserted trading advantage.